^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Bylantra (devimistat) (PDH inhibitor, α-KGDH inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
Published date:
11/10/2020
Excerpt:
...Rafael Pharmaceuticals, Inc....today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer.
